CollPlant Biotechnologies (CLGN) Other financing activities (2020 - 2024)
CollPlant Biotechnologies' (CLGN) quarterly Other financing activities came in at $9000.0 in Q1 2024, down 98.88% YoY from $803000.0 in Q2 2023, and down 95.83% on a QoQ basis from $216000.0 in Q3 2023.
CollPlant Biotechnologies (CLGN) Other financing activities (2020 - 2024) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 5 years of Other financing activities data on file, last reported at $9000.0 in Q1 2024.
- Quarterly Other financing activities fell 98.88% year-over-year to $9000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $9000.0 (down 99.19% YoY) and the FY2025 annual result came in at $5.6 million, up 62022.22% from the prior year.
- Other financing activities slipped to $9000.0 in Q1 2024, from $216000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $5.8 million in Q1 2020 to a low of -$5.7 million in Q2 2020.
- A 5-year average of $895285.7 and a median of $601500.0 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities surged 181.69% — and 2024, when it sank 98.88%.
- Tracing CLGN's Other financing activities over 5 years: stood at -$1.7 million in 2020, then jumped by 108.4% to $142000.0 in 2021, then jumped by 181.69% to $400000.0 in 2022, then sank by 46.0% to $216000.0 in 2023, then tumbled by 95.83% to $9000.0 in 2024.
- The last three Other financing activities figures came in at $9000.0 (Q1 2024), $216000.0 (Q3 2023), and $89000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | CollPlant Biotechnologies | 4.23 Mn | 4.23 Mn | -243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Sep 30, 2023 | 216,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Mar 31, 2023 | 803,000.00 |
| Mar 31, 2023 | 803,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Mar 31, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 142,000.00 |
| Dec 31, 2021 | 142,000.00 |
| Sep 30, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.36 Mn |
| Jun 30, 2021 | 1.36 Mn |
| Mar 31, 2021 | 2.77 Mn |
| Mar 31, 2021 | 2.77 Mn |